

Application No. 09/976,468  
Amendment dated January 28, 2005  
Reply to Office Action mailed November 22, 2004

**Amendments to the Claims:**

1-44. (Canceled without Prejudice)

45. (Currently Amended) A method for preventing or reducing the risk of developing graft-versus-host disease in a human patient who is a recipient of an organ or tissue transplant, comprising:

administering to the transplant recipient pentostatin in a pharmaceutically effective amount of about 1-10 mg/m<sup>2</sup> or about 0.05-5 mg/m<sup>2</sup> within a predetermined time window before the transplantation.

46. (Previously presented) The method claim 45, wherein the transplant recipient is transplanted with bone marrow.

47. (Previously presented) The method of claim 45, wherein the transplant recipient is transplanted with hematopoietic stem cells.

48. (Previously presented) The method of claim 45, wherein the transplant patient is transplanted with hematopoietic stem cells and treated in a myeloablative conditioning regimen.

49. (Previously presented) The method of claim 45, wherein pentostatin is administered orally to the transplant recipient.

50. (Previously presented) The method of claim 45, wherein pentostatin is administered parenterally to the transplant recipient.

51. (Currently Amended) The method of claim 45, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose ~~between~~ of about 1-10 mg/m<sup>2</sup>.

52. (Currently Amended) The method of claim 45, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose ~~between~~ of about 2-6 mg/m<sup>2</sup>.

Application No. 09/976,468  
Amendment dated January 28, 2005  
Reply to Office Action mailed November 22, 2004

53. (Currently Amended) The method of claim 45, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose ~~between~~ of about 0.1-2 mg/m<sup>2</sup>.

54. (Currently Amended) The method of claim 45, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose ~~between~~ of about 0.5-1 mg/m<sup>2</sup>.

55. (Canceled without Prejudice).

56. (Previously presented) The method of claim 45, further comprising: administering to the transplant recipient an immunosuppressive agent selected from the group consisting of prednisone, methylprednisolone, cyclophosphamide, cyclosporin A, FK506, thalidomide, azathioprine, Daclizumab, Infliximab, MEDI-205, abx-cbl and ATG.

57. (New) The method of claim 45, wherein pentostatin is administered to the patient 2 or 3 days before the transplantation.

58. (New) A method for preventing or reducing the risk of developing graft-versus-host disease in a patient who is a recipient of an organ or tissue transplant, comprising:  
administering to the transplant recipient pentostatin in a pharmaceutically effective amount within a predetermined time window after the transplantation.

59. (New) The method claim 58, wherein the transplant recipient is transplanted with bone marrow.

60. (New) The method of claim 58, wherein the transplant recipient is transplanted with hematopoietic stem cells.

61. (New) The method of claim 58, wherein the transplant patient is transplanted with hematopoietic stem cells and treated in a myeloablative conditioning regimen.

Application No. 09/976,468  
Amendment dated January 28, 2005  
Reply to Office Action mailed November 22, 2004

62. (New) The method of claim 58, wherein pentostatin is administered orally to the transplant recipient.

63. (New) The method of claim 58, wherein pentostatin is administered parenterally to the transplant recipient.

64. (New) The method of claim 58, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose of about 1-10 mg/m<sup>2</sup>.

65. (New) The method of claim 58, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose of about 2-6 mg/m<sup>2</sup>.

67. (New) The method of claim 58, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose of about 0.1-2 mg/m<sup>2</sup>.

68. (New) The method of claim 58, wherein pentostatin is administered to the transplant recipient by intravenous infusion at a dose of about 0.5-1 mg/m<sup>2</sup>.

69. (New) The method of claim 58, further comprising: administering to the transplant recipient an immunosuppressive agent selected from the group consisting of prednisone, methylprednisolone, cyclophosphamide, cyclosporin A, FK506, thalidomide, azathioprine, Daclizumab, Infliximab, MEDI-205, abx-cbl and ATG.

70. (New) The method of claim 58, wherein pentostatin is administered to the patient 2 or 3 days before the transplantation.